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unusual?We read with great interest the excellent editorial titled “Stem
the tide” on the newly implementation of the conditional and
time-limited authorization system for regenerative medicine prod-
ucts in Japan (see Nature 528, 163e164, 2015 [1]). The editor high-
lighted the introduction of unproven system or the overhaul of drug
regulation to create a fast track to bring regenerative therapy to
market in Japan. That system may have several problems in the ef-
ﬁcacy and cost allocation of regenerative medicine products, and
raise a concern about ﬂoods of unsuccessful treatments in the
country. The author also mentioned that the strategy for establish-
ing the fastest way to meet the patient's needs is working. Because
the ﬁrst regenerative medicine product, HeartSheet was approved
by Japanese regulatory authority (Ministry of Health, Labour and
Welfare) on September 18, 2015 [2] under the new act. Finally,
the editor argues that regulatory agencies around the world should
resist pressure from biotech companies to create such fast-track
system.
However, there exist similar expedited approval systems such as
“accelerated approval” of drugs and biologics for serious or life-
threatening illnesses in the US (21 CFR314 subpart E and
21CFR601 subpart E), “conditional market authorization” of drugs
for serious and life-threating diseases, in emergency situation,
and orphan diseases (Commission Regulation (EC) No 507/2006),
and “market authorization under exceptional circumstance” of
drugs in the EU (Regulation (EC) No 726/2004). The most of
approved therapeutic products are intended to treat a variety of
cancers and human immunodeﬁciency virus disease.
Just focused on regenerative medicine products, Carticel™
which was derived from autologous chondrocytes was approved
by the accelerated approval of biological products for serious or
life-threating illness on August 22, 1997 in the US [3]. Then, a con-
ditional marketing authorization was granted to Holoclar, which
was derived from autologous limbal stem cells advanced-therapy
medicinal product (ATMP) on February 17, 2015 [4]. Furthermore,
a marketing authorization under exceptional circumstance was
granted to Glybera on October 25, 2012, which became the ﬁrst
gene therapy product approved in developed countries [5].
In principle, the beneﬁt and risk of any therapeutic products,
including products called “regenerative medicine products” in
Japan, “human cells, tissues, and cellular and tissue-based products
(HCT/Ps)” in the US, or “ATMP” in the EU, have to be sufﬁciently
evaluated at the stage of marketing authorization application.Peer review under responsibility of the Japanese Society for Regenerative
Medicine.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).However, the beneﬁt of some products for rare, severe, degenerat-
ing or life-threatening diseases may not be able to be proven
enough, because of a limited number of patients during a limited
period of clinical trials, or limited scientiﬁc knowledge for relevant
diseases. Expedited approval pathways are expected to provide pa-
tients suffered from serious, debilitating and currently untreatable
diseases with new opportunities of treatment. Of course, follow-up
has to be conducted for all patients treated with regenerative med-
icine products that are approved under Japan's new regulation, to
monitor not only their adverse events, but also their efﬁcacy.
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